{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:04:43Z","timestamp":1792587883969,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T00:00:00Z","timestamp":1501718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1038\/gt.2017.71","type":"journal-article","created":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T14:41:50Z","timestamp":1501771310000},"page":"630-639","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":107,"title":["AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington\u2019s disease"],"prefix":"10.1038","volume":"24","author":[{"given":"J","family":"Miniarikova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Martier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C C","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Pythoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Richetin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Lubelski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M M","family":"Evers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S J","family":"van Deventer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Petry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"D\u00e9glon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Konstantinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,3]]},"reference":[{"key":"BFgt201771_CR1","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000443738","volume":"46","author":"MD Rawlins","year":"2016","unstructured":"Rawlins MD, Wexler NS, Wexler AR, Tabrizi SJ, Douglas I, Evans SJW et al. The prevalence of huntington\u2019s disease. Neuroepidemiology 2016; 46: 144\u2013153.","journal-title":"Neuroepidemiology"},{"key":"BFgt201771_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","volume":"65","author":"DR Langbehn","year":"2004","unstructured":"Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR . A new model for prediction of the age of onset and penetrance for Huntington\u2019s disease based on CAG length. Clin Genet 2004; 65: 267\u2013277.","journal-title":"Clin Genet"},{"key":"BFgt201771_CR3","doi-asserted-by":"crossref","unstructured":"The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971\u2013983.","DOI":"10.1016\/0092-8674(93)90585-E"},{"key":"BFgt201771_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","volume":"10","author":"CA Ross","year":"2011","unstructured":"Ross CA, Tabrizi SJ . Huntington\u2019s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011; 10: 83\u201398.","journal-title":"Lancet Neurol"},{"key":"BFgt201771_CR5","doi-asserted-by":"publisher","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","volume":"1","author":"GP Bates","year":"2015","unstructured":"Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR et al. Huntington disease. Nat Rev Dis Primers 2015; 1: 15005.","journal-title":"Nat Rev Dis Primers"},{"key":"BFgt201771_CR6","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","volume":"277","author":"M DiFiglia","year":"1997","unstructured":"DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997; 277: 1990\u20131993.","journal-title":"Science"},{"key":"BFgt201771_CR7","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","volume":"10","author":"CA Ross","year":"2014","unstructured":"Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 2014; 10: 204\u2013216.","journal-title":"Nat Rev Neurol"},{"key":"BFgt201771_CR8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)80623-6","volume":"101","author":"A Yamamoto","year":"2000","unstructured":"Yamamoto A, Lucas JJ, Hen R . Reversal of neuropathology and motor dysfunction in a conditional model of Huntington\u2019s disease. Cell 2000; 101: 57\u201366.","journal-title":"Cell"},{"key":"BFgt201771_CR9","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/35888","volume":"391","author":"A Fire","year":"1998","unstructured":"Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC . Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806\u2013811.","journal-title":"Nature"},{"key":"BFgt201771_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/hmg\/ddr137","volume":"20","author":"RL Boudreau","year":"2011","unstructured":"Boudreau RL, Rodr\u00edguez-Lebr\u00f3n E, Davidson BL . RNAi medicine for the brain: progresses and challenges. Hum Mol Genet 2011; 20: 21\u201327.","journal-title":"Hum Mol Genet"},{"key":"BFgt201771_CR11","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/mds.26020","volume":"29","author":"N Aronin","year":"2014","unstructured":"Aronin N, DiFiglia M . Huntingtin-lowering strategies in Huntington\u2019s disease: antisense oligonucleotides, small RNAs, and gene editing. Mov Disord 2014; 29: 1455\u20131461.","journal-title":"Mov Disord"},{"key":"BFgt201771_CR12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/B978-0-12-800149-3.00003-2","volume":"87","author":"B Kantor","year":"2014","unstructured":"Kantor B, Bailey RM, Wimberly K, Kalburgi SN, Gray SJ . Methods For Gene Transfer To The Central Nervous System. Adv Genet 2014; 87: 125\u2013197.","journal-title":"Adv Genet"},{"key":"BFgt201771_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.coviro.2016.08.003","volume":"21","author":"A Srivastava","year":"2016","unstructured":"Srivastava A . In vivo tissue-tropism of adeno-associated viral vectors. Curr Opin Virol 2016; 21: 75\u201380.","journal-title":"Curr Opin Virol"},{"key":"BFgt201771_CR14","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/mt.2009.286","volume":"18","author":"EA Markakis","year":"2010","unstructured":"Markakis EA, Vives KP, Bober J, Leichtle S, Leranth C, Beecham J et al. Comparative transduction efficiency of AAV vector serotypes 1\u20136 in the substantia nigra and striatum of the primate brain. Mol Ther 2010; 18: 588\u2013593.","journal-title":"Mol Ther"},{"key":"BFgt201771_CR15","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ymthe.2004.05.024","volume":"10","author":"C Burger","year":"2004","unstructured":"Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 2004; 10: 302\u2013317.","journal-title":"Mol Ther"},{"key":"BFgt201771_CR16","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.ymthe.2005.04.019","volume":"12","author":"D Lin","year":"2005","unstructured":"Lin D, Fantz CR, Levy B, Rafi MA, Vogler C, Wenger DA et al. AAV2\/5 vector expressing galactocerebrosidase ameliorates CNS disease in the murine model of globoid-cell leukodystrophy more efficiently than AAV2. Mol Ther 2005; 12: 422\u2013430.","journal-title":"Mol Ther"},{"key":"BFgt201771_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/gt.2017.14","volume":"24","author":"L Samaranch","year":"2017","unstructured":"Samaranch L, Blits B, San Sebastian W, Hadaczek P, Bringas J, Sudhakar V et al. MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain. Gene Ther 2017; 24: 253\u2013261.","journal-title":"Gene Ther"},{"key":"BFgt201771_CR18","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1038\/mtna.2016.7","volume":"5","author":"J Miniarikova","year":"2016","unstructured":"Miniarikova J, Zanella I, Huseinovic A, van der Zon T, Hanemaaijer E, Martier R et al. Design, characterization, and lead selection of therapeutic miRNAs targeting huntingtin for development of gene therapy for Huntington\u2019s disease. Mol Ther Nucleic Acids 2016; 5: e297.","journal-title":"Mol Ther Nucleic Acids"},{"key":"BFgt201771_CR19","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1002\/mds.26006","volume":"29","author":"L Menalled","year":"2014","unstructured":"Menalled L, Brunner D . Animal models of Huntington\u2019s disease for translation to the clinic: best practices. Mov Disord 2014; 29: 1375\u20131390.","journal-title":"Mov Disord"},{"key":"BFgt201771_CR20","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/ilar.48.4.356","volume":"48","author":"S Ramaswamy","year":"2007","unstructured":"Ramaswamy S, Mcbride JL, Kordower JH . Animal models of Huntington\u2019s disease. ILAR J 2007; 48: 356\u2013373.","journal-title":"ILAR J"},{"key":"BFgt201771_CR21","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/nrn3570","volume":"14","author":"MA Pouladi","year":"2013","unstructured":"Pouladi MA, Morton AJ, Hayden MR . Choosing an animal model for the study of Huntington\u2019s disease. Nat Rev Neurosci 2013; 14: 708\u2013721.","journal-title":"Nat Rev Neurosci"},{"key":"BFgt201771_CR22","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1523\/JNEUROSCI.22-09-03473.2002","volume":"22","author":"LP de Almeida","year":"2002","unstructured":"de Almeida LP, Ross CA, Zala D, Aebischer P, D\u00e9glon N . Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J Neurosci 2002; 22: 3473\u20133483.","journal-title":"J Neurosci"},{"key":"BFgt201771_CR23","doi-asserted-by":"publisher","first-page":"e99341","DOI":"10.1371\/journal.pone.0099341","volume":"9","author":"V Drouet","year":"2014","unstructured":"Drouet V, Ruiz M, Zala D, Feyeux M, Auregan G, Cambon K et al. Allele-specific silencing of mutant huntingtin in rodent brain and human stem cells. PLoS ONE 2014; 9: e99341.","journal-title":"PLoS ONE"},{"key":"BFgt201771_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S0006-8993(98)00724-0","volume":"808","author":"CC Ouimet","year":"1998","unstructured":"Ouimet CC, Langley-Gullion KC, Greengard P . Quantitative immunocytochemistry of DARPP-32-expressing neurons in the rat caudatoputamen. Brain Res 1998; 808: 8\u201312.","journal-title":"Brain Res"},{"key":"BFgt201771_CR25","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.expneurol.2009.03.004","volume":"217","author":"MS Lombardi","year":"2009","unstructured":"Lombardi MS, Jaspers L, Spronkmans C, Gellera C, Taroni F, Di Maria E et al. A majority of Huntington\u2019s disease patients may be treatable by individualized allele-specific RNA interference. Exp Neurol 2009; 217: 312\u2013319.","journal-title":"Exp Neurol"},{"key":"BFgt201771_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1006\/exnr.2002.7942","volume":"176","author":"RL Klein","year":"2002","unstructured":"Klein RL, Hamby ME, Gong Y, Hirko AC, Wang S, Hughes JA et al. Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain. Exp Neurol 2002; 176: 66\u201374.","journal-title":"Exp Neurol"},{"key":"BFgt201771_CR27","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1038\/mtna.2014.27","volume":"3","author":"H Ma","year":"2014","unstructured":"Ma H, Zhang J, Wu H . Designing Ago2-specific siRNA\/shRNA to avoid competition with endogenous miRNAs. Mol Ther Nucleic Acids 2014; 3: e176.","journal-title":"Mol Ther Nucleic Acids"},{"key":"BFgt201771_CR28","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1261\/rna.043950.113","volume":"20","author":"E Herrera-Carrillo","year":"2014","unstructured":"Herrera-Carrillo E, Harwig A, Liu YP, Berkhout B . Probing the shRNA characteristics that hinder Dicer recognition and consequently allow Ago-mediated processing and AgoshRNA activity. RNA 2014; 20: 1410\u20131418.","journal-title":"RNA"},{"key":"BFgt201771_CR29","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.cell.2012.08.002","volume":"150","author":"D Yu","year":"2012","unstructured":"Yu D, Pendergraff H, Liu J, Kordasiewicz HB, Cleveland DW, Swayze EE et al. Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell 2012; 150: 895\u2013908.","journal-title":"Cell"},{"key":"BFgt201771_CR30","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1038\/mt.2011.201","volume":"19","author":"JB Carroll","year":"2011","unstructured":"Carroll JB, Warby SC, Southwell AL, Doty CN, Greenlee S, Skotte N et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene\/allele-specific silencing of mutant huntingtin. Mol Ther 2011; 19: 2178\u20132185.","journal-title":"Mol Ther"},{"key":"BFgt201771_CR31","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","volume":"19","author":"EL Pfister","year":"2009","unstructured":"Pfister EL, Kennington L, Straubhaar J, Wagh S, Liu W, DiFiglia M et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients. Curr Biol 2009; 19: 774\u2013778.","journal-title":"Curr Biol"},{"key":"BFgt201771_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/cge.12385","volume":"86","author":"C Kay","year":"2014","unstructured":"Kay C, Skotte NH, Southwell AL, Hayden MR . Personalized gene silencing therapeutics for Huntington disease. Clin Genet 2014; 86: 29\u201336.","journal-title":"Clin Genet"},{"key":"BFgt201771_CR33","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ajhg.2009.02.003","volume":"84","author":"SC Warby","year":"2009","unstructured":"Warby SC, Montpetit A, Hayden AR, Carroll JB, Butland SL, Visscher H et al. CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. Am J Hum Genet 2009; 84: 351\u2013366.","journal-title":"Am J Hum Genet"},{"key":"BFgt201771_CR34","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/1471-2164-8-126","volume":"8","author":"SL Butland","year":"2007","unstructured":"Butland SL, Devon RS, Huang Y, Mead C-L, Meynert AM, Neal SJ et al. CAG-encoded polyglutamine length polymorphism in the human genome. BMC Genomics 2007; 8: 126.","journal-title":"BMC Genomics"},{"key":"BFgt201771_CR35","doi-asserted-by":"publisher","first-page":"e234","DOI":"10.1038\/mtna.2015.7","volume":"4","author":"AM Monteys","year":"2015","unstructured":"Monteys AM, Wilson MJ, Boudreau RL, Spengler RM, Davidson BL . Artificial miRNAs targeting mutant huntingtin show preferential silencing in vitro and in vivo. Mol Ther Nucleic Acids 2015; 4: e234.","journal-title":"Mol Ther Nucleic Acids"},{"key":"BFgt201771_CR36","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","volume":"136","author":"DP Bartel","year":"2004","unstructured":"Bartel DP . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 136: 215\u2013233.","journal-title":"Cell"},{"key":"BFgt201771_CR37","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.expneurol.2011.11.020","volume":"233","author":"DK Stiles","year":"2012","unstructured":"Stiles DK, Zhang Z, Ge P, Nelson B, Grondin R, Ai Y et al. Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Exp Neurol 2012; 233: 463\u2013471.","journal-title":"Exp Neurol"},{"key":"BFgt201771_CR38","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1038\/mt.2011.219","volume":"19","author":"JL McBride","year":"2011","unstructured":"McBride JL, Pitzer MR, Boudreau RL, Dufour B, Hobbs T, Ojeda SR et al. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington\u2019s disease. Mol Ther 2011; 19: 2152\u20132162.","journal-title":"Mol Ther"},{"key":"BFgt201771_CR39","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/brain\/awr333","volume":"135","author":"R Grondin","year":"2012","unstructured":"Grondin R, Kaytor MD, Ai Y, Nelson PT, Thakker DR, Heisel J et al. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain 2012; 135: 1197\u20131209.","journal-title":"Brain"},{"key":"BFgt201771_CR40","doi-asserted-by":"publisher","first-page":"5587","DOI":"10.1523\/JNEUROSCI.20-15-05587.2000","volume":"20","author":"AF Hottinger","year":"2000","unstructured":"Hottinger AF, Azzouz M, D\u00e9glon N, Aebischer P, Zurn AD . Complete and long-term rescue of lesioned adult motoneurons by lentiviral-mediated expression of glial cell line-derived neurotrophic factor in the facial nucleus. J Neurosci 2000; 20: 5587\u20135593.","journal-title":"J Neurosci"},{"key":"BFgt201771_CR41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0378-1119(87)90214-9","volume":"60","author":"CN Adra","year":"1987","unstructured":"Adra CN, Boer PH, McBurney MW . Cloning and expression of the mouse pgk-1 gene and the nucleotide sequence of its promoter. Gene 1987; 60: 65\u201374.","journal-title":"Gene"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/gt201771.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/gt201771","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/gt.2017.71","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/gt201771.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:34:28Z","timestamp":1684431268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/gt201771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,3]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["BFgt201771"],"URL":"https:\/\/doi.org\/10.1038\/gt.2017.71","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,3]]},"assertion":[{"value":"19 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JM, RM, CCB, JL, MME, HP and PK are employees and shareholders at uniQure. ND and CHUV have a collaborative agreement with uniQure. uniQure has sponsored a portion of the research performed in ND lab.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}